Match each patient's clinical presentation of an antipsychotic-associated complication to the most appropriate next step in pharmacological or clinical management.
- A 24-year-old man presents with severe diaphoresis, hyperthermia, 'lead-pipe' muscle rigidity, and altered mental status one week after starting a high-potency first-generation antipsychotic.Discontinue the current medication, initiate aggressive supportive care, and administer dantrolene or bromocriptine.
- A 35-year-old woman treated with a first-generation antipsychotic for five years develops involuntary, repetitive lip smacking, facial grimacing, and choreoathetoid movements of the tongue.Taper the current medication and consider starting a vesicular monoamine transporter 2 (VMAT2) inhibitor.
- A 28-year-old man receiving treatment for refractory schizophrenia is found to have an absolute neutrophil count of 400/μL during routine laboratory monitoring.Immediately stop the current medication, admit the patient, and closely monitor for signs of severe infection.
- A 42-year-old man acutely develops a painful, sustained upward deviation of the eyes and severe torticollis hours after receiving an intramuscular antipsychotic in the emergency department.Administer an intramuscular or intravenous anticholinergic agent, such as benztropine or diphenhydramine.
- A 30-year-old woman taking an antipsychotic for schizoaffective disorder presents with new-onset bilateral galactorrhea, breast tenderness, and secondary amenorrhea.Cross-taper the offending agent to a partial D2 receptor agonist, such as aripiprazole.
Cevap
Each clinical presentation describes a unique antipsychotic-associated adverse effect that pairs with its definitive next step in management: NMS requires dantrolene/bromocriptine; Tardive Dyskinesia requires a VMAT2 inhibitor; Clozapine-induced agranulocytosis requires immediate drug cessation; Acute Dystonia requires an anticholinergic agent; and Hyperprolactinemia requires switching to a D2 partial agonist.
Each pair matches a classic clinical presentation of an antipsychotic side effect with its established standard of care: NMS is a life-threatening emergency requiring aggressive cooling and dantrolene or bromocriptine. Tardive Dyskinesia is managed by lowering the dose or adding a VMAT2 inhibitor. Clozapine-induced severe neutropenia demands immediate cessation of the drug. Acute Dystonia is rapidly reversed with intramuscular anticholinergics. Hyperprolactinemia is managed by switching to a prolactin-sparing agent such as aripiprazole.
Adım Adım Çözüm
Anahtar Kavram
Management of antipsychotic adverse effects requires accurate identification of the clinical syndrome and targeted interventions: anticholinergics for acute dystonia, VMAT2 inhibitors for tardive dyskinesia, dantrolene/bromocriptine for NMS, and D2 partial agonists for hyperprolactinemia.